What are the current treatment recommendations for pancreatic cancer across stages (localized, borderline resectable, locally advanced, and metastatic)?

Pancreatic Cancer Management

For metastatic pancreatic cancer with good performance status, use FOLFIRINOX as first-line therapy; for resectable disease, proceed with upfront surgery followed by 6 months of adjuvant gemcitabine or 5-FU; for borderline resectable or locally advanced disease, initiate neoadjuvant chemotherapy to achieve downstaging before considering resection.

Treatment by Stage

Resectable Disease

Surgical resection remains the only curative option and should be performed upfront for anatomically resectable tumors 1, 2. The NCCN criteria define resectability based on vessel involvement—specifically the relationship between tumor and superior mesenteric vein/portal vein, superior mesenteric artery, celiac trunk, and common hepatic artery 2.

Surgical approach:

• Pancreatoduodenectomy (Whipple procedure) for head tumors with dissection of the right hemi-circumference of the SMA 2
• Distal pancreatectomy with splenectomy for body/tail tumors 2
• Venous resection (PV/SMV) is acceptable when needed for R0 resection, though associated with lower R0 rates and poorer survival 2
• R0 resection defined as no cancer cells within 1 mm of all margins 2

Adjuvant therapy is mandatory: Postoperatively, administer 6 months of gemcitabine (1000 mg/m² over 30 minutes, weekly for 3 weeks every 28 days) or 5-FU chemotherapy 1. This applies even after R1 resection 1. Modified FOLFIRINOX should be considered for patients who can tolerate it 3.

Critical pitfall: Chemoradiation in the adjuvant setting should only be performed within randomized controlled trials—it is not standard practice 1.

Borderline Resectable Disease

Neoadjuvant chemotherapy is the preferred approach for borderline resectable tumors to achieve downstaging and improve R0 resection rates 1, 4, 5. These are tumors with limited vessel encasement that may become resectable after systemic therapy.

Treatment sequence:

1. Induction chemotherapy (FOLFIRINOX or gemcitabine-based regimens) for 2-6 months
2. Restaging with multiphasic CT
3. Surgical resection if downstaged to resectable status
4. Complete adjuvant chemotherapy to total 6 months perioperative therapy

Patients who develop metastases during neoadjuvant therapy or progress locally are not surgical candidates 1.

Locally Advanced Unresectable Disease

For locally advanced disease without metastases, initiate systemic chemotherapy with the same regimens used for metastatic disease 1. Gemcitabine at conventional dosing (1000 mg/m² over 30 minutes) is recommended 1.

Selective use of radiation: Ablative-dose stereotactic body radiation therapy may offer durable local control in highly selected responders after induction chemotherapy, though survival benefits remain investigational 5. Conventional chemoradiation should not be used as standard first-line treatment 1.

Reassess for resectability after 2-4 months of chemotherapy—some patients may convert to resectable status 1, 4.

Metastatic Disease

First-Line Therapy

For patients ≤75 years with ECOG PS 0-1 and bilirubin ≤1.5× ULN, FOLFIRINOX is the preferred regimen (Category 1) 6, 1, 6. This provides significant improvement in overall survival compared to gemcitabine alone 1.

Alternative first-line options for good performance status patients:

• Gemcitabine + nab-paclitaxel (Category 2B) 6
• Gemcitabine + erlotinib (Category 1)—continue erlotinib only if skin rash develops within first 8 weeks 6, 1, 6
• Gemcitabine + capecitabine 6
• Gemcitabine + cisplatin (especially for hereditary cancers with BRCA mutations) 6

For patients with poor performance status or unable to tolerate combination therapy:

• Gemcitabine monotherapy 1000 mg/m² over 30 minutes, weekly for 3 weeks every 28 days (Category 1) 6, 1, 6
• Capecitabine monotherapy (Category 2B) 6

Important caveat: Combinations of gemcitabine with other cytotoxic agents (5-FU, capecitabine, irinotecan, platinum) do not confer significant survival advantage in large phase III trials and should not be used as standard first-line treatment outside the specific regimens listed above 1.

Second-Line Therapy

For patients previously treated with gemcitabine-based regimens:

• 5-FU/leucovorin/oxaliplatin (FOLFOX) or capecitabine/oxaliplatin (CapeOx)—the CONKO 003 trial demonstrated significant overall survival improvement with oxaliplatin addition 6, 1, 6
• Capecitabine 1000 mg/m² PO twice daily, days 1-14 every 21 days 6

For patients treated with first-line FOLFIRINOX:

• Gemcitabine-based regimens can be considered 1

Essential Molecular Testing

Perform germline testing for all patients with pancreatic cancer to identify hereditary cancer syndromes (BRCA1/2, ATM, mismatch repair genes) 7, 3, 8. This informs treatment selection—particularly platinum-based therapy and PARP inhibitors for BRCA-mutated tumors 7, 8.

Consider somatic molecular profiling for metastatic disease to identify actionable alterations including MSI-high/dMMR status, NTRK fusions, and other targetable mutations 3, 8.

Key Clinical Principles

Enrollment in clinical trials is strongly encouraged at all disease stages 6.

Multidisciplinary tumor board discussion in expert centers is required to define treatment strategy 2.

Goals of systemic therapy must be discussed with patients prior to initiation, and close follow-up during chemotherapy is mandatory 6.

Nutritional status and performance status are critical determinants of treatment tolerance and should guide regimen selection 2.